Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAOB | P27338 | 7/20 | 0.62 |
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.57 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15238912 | 1.00 | MEN1 (0.69) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL811912 | 1.00 | MEN1 (0.69) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL9778220 | 0.85 | MEN1 (0.69) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL11702342 | 0.85 | MEN1 (0.69) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL13710801 | 0.84 | MEN1 (0.62) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL5020752 | 0.83 | HDAC1 (0.77) | MEN1KMT2AMAPTTDP1 | |
| SCHEMBL277169 | 0.83 | MEN1 (0.71) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL27971259 | 0.83 | MAOB (0.63) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL27888906 | 0.83 | MAOB (0.63) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL42325 | 0.83 | MEN1 (0.71) | MEN1KMT2AMAOBMAOABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4431567-A2 | PROCESS FOR STABILIZING A COMPOSITION OF POLYARYL-ETHER-KETONE (PAEK) | ARKEMA FRANCE (FR) | 2024-09-18 | — | — | EP | claimed |
| CN-117624864-A | Chemical-resistant polycarbonate composition and preparation method thereof | 广东圆融新材料有限公司 | 2024-03-01 | — | — | CN | claimed |
| EP-4292586-A1 | GUANFACINE HYDROCHLORIDE CONTAINING PHARMACEUTICAL PREPARATION | Sawai Pharmaceutical Co., Ltd. (JP) | 2023-12-20 | — | — | EP | claimed |
| EP-4292587-A1 | GUANFACINE HYDROCHLORIDE CONTAINING PHARMACEUTICAL PREPARATION | Sawai Pharmaceutical Co., Ltd. (JP) | 2023-12-20 | — | — | EP | claimed |
| WO-2023197401-A1 | BIOLOGICAL GEL FORMULATION, METHOD FOR PREPARING SAME, AND USE THEREOF | 臻赫医药(杭州)有限公司 | 2023-10-19 | — | — | WO | claimed |
| CN-116440072-A | Single-dose atropine ophthalmic composition for delaying myopia progression and BFS sterile production method thereof | 北京中科利华医药研究院有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-115708800-A | Eye drop composition of sitagliptin and tea polyphenol | 上海博悦生物科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| CN-115252916-A | Medical hollow magnesium or magnesium alloy implant and preparation method thereof | 大博医疗科技股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115154655-A | Medical metal implant and processing method thereof | 大博医疗科技股份有限公司 | 2022-10-11 | — | — | CN | claimed |
| WO-2022135343-A1 | VILAZODONE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海博志研新药物技术有限公司 | 2022-06-30 | — | — | WO | claimed |
| WO-2022121961-A1 | FULVESTRANT PHARMACEUTICAL COMPOSITION, PREPARATION THEREFOR, AND APPLICATION THEREOF | 上海博志研新药物技术有限公司 | 2022-06-16 | — | — | WO | claimed |
| CN-109652463-A | A method of using Perakine reductase synthesis of chiral alcohol | 浙江大学 | 2019-04-19 | — | — | CN | claimed |
| EP-4659755-A1 | THERAPEUTIC DRUG FOR RETINAL PIGMENT EPITHELIUM TEARS | RACTHERA Co., Ltd. (JP) | 2025-12-10 | — | — | EP | disclosed |
| EP-4654902-A1 | MEDICAL DEVICE FOR REGENERATING BONE AND A METHOD OF MANUFACTURE THEREOF | PBC Innovations Limited (IE) | 2025-12-03 | — | — | EP | disclosed |
| US-12465593-B2 | Pharmaceutical composition | ASTRAZENECA AB (SE) | 2025-11-11 | — | — | US | disclosed |
| EP-4595952-A1 | OPHTHALMIC COMPOSITION COMPRISING BRIMONIDINE | Taejoon Pharmaceutical Co., Ltd. (KR) | 2025-08-06 | — | — | EP | disclosed |
| EP-0034349-B1 | NOVEL PYRIDINECARBOXAMIDE DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF, THE USE OF SAID DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Seiyaku Co., Ltd. (JP) | 1983-12-14 | — | — | EP | disclosed |
| US-4332809-A | ANTIALLERGENS | TANABE SEIYAKU CO., LTD. (JP) | 1982-06-01 | — | — | US | disclosed |
| EP-0034349-A2 | Novel pyridinecarboxamide derivatives, a process for the preparation thereof, the use of said derivatives and a pharmaceutical composition containing same | Tanabe Seiyaku Co., Ltd. (JP) | 1981-08-26 | — | — | EP | disclosed |
| US-3989708-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465593-B2 | Pharmaceutical composition | CYP3A7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT2B7 | MEN1 2963/4885KMT2A 1214/4885MAOB 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.